The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells
Open accessAbstract
The envelope glycoprotein of human immunodeficiency virus (HIV) consists of an exterior glycoprotein (gp120) and a trans-membrane domain (gp41) and has an important role in viral entry into cells. HIV-1 entry has been validated as a clinically relevant anti-viral strategy for drug discovery. In the present work, several 2'-F substituted RNA aptamers that bind to the HIV-1(BaL) gp120 protein with nanomole affinity were isolated from a RNA library by the SELEX (Systematic Evolution of Ligands by EXponential enrichment) procedure. From two of these aptamers we created a series of new dual inhibitory function anti-gp120 aptamer-siRNA chimeras. The aptamers and aptamer-siRNA chimeras specifically bind to and are internalized into cells expressing HIV gp160. The Dicer-substrate siRNA delivered by the aptamers is functionally processed by Dicer, resulting in specific inhibition of HIV-1 replication and infectivity in cultured CEM T-cells and primary blood mononuclear cells (PBMCs). Moreover, we have introduced a 'sticky' sequence onto a chemically synthesized aptamer which facilitates attachment of the Dicer substrate siRNAs for potential multiplexing. Our results provide a set of novel inhibitory agents for blocking HIV replication and further validate the use of aptamers for delivery of Dicer substrate siRNAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,533
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J.-C., & Montagnier, L. (1984) · Nature · doi:10.1038/312767a0 · Cited by 2,436
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Identification of host proteins required for HIV infection through a functional genomic screen
Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., & Elledge, S. J. (2008) · Science · doi:10.1126/science.1152725 · Cited by 1,449 · cited 1×
“It has been demonstrated that more than 250 HIV-dependency factors (HDFs) are required by HIV infection ( 48 ).”
BackgroundChan, D. C., & Kim, P. S. (1998) · Cell · doi:10.1016/s0092-8674(00)81430-0 · Cited by 1,277
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613
Lupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen
Smith, D. H., Byrn, R. A., Marsters, S. A., Gregory, T., Groopman, J. E., & Capon, D. J. (1987) · Science · doi:10.1126/science.3500514 · Cited by 485
Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway, G. P., Katinger, H., Barbas, C. F., Burton, D. R., & Ho, D. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6609-6617.1995 · Cited by 480
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation
Hussey, R. E., Richardson, N. E., Kowalski, M., Brown, N. R., Chang, H.-C., Siliciano, R. F., Dorfman, T., Walker, B., Sodroski, J., & Reinherz, E. L. (1988) · Nature · doi:10.1038/331078a0 · Cited by 427
RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.
Tuerk, C., MacDougal, S., & Gold, L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6988 · Cited by 415
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832214100 · Cited by 357
Functional polarity is introduced by Dicer processing of short substrate RNAs
Rose, S. D. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki732 · Cited by 312
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Self-citationTwenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells
Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4583 · Cited by 284
The entry of entry inhibitors: A fusion of science and medicine
Moore, J. P., & Doms, R. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1932511100 · Cited by 278
Nanoparticle–aptamer bioconjugates for cancer targeting
Farokhzad, O. C., Karp, J. M., & Langer, R. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.3.311 · Cited by 256
Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
Kilby, J. M., & Eron, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022812 · Cited by 254
HIV-1 attachment: another look
Ugolini, S., Mondor, I., & Sattentau, Q. J. (1999) · Trends in Microbiology · doi:10.1016/s0966-842x(99)01474-2 · Cited by 229
Alternative drug formulations of docetaxel: a review
Engels, F. K., Mathot, R. A. A., & Verweij, J. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280113338 · Cited by 211
Dey, B., Lerner, D. L., Lusso, P., Boyd, M. R., Elder, J. H., & Berger, E. A. (2000) · Journal of Virology · doi:10.1128/.74.10.4562-4569.2000 · Cited by 210
Indicator Cell Lines for Detection of Primary Strains of Human and Simian Immunodeficiency Viruses
Vodicka, M. A., Goh, W. C., Wu, L. I., Rogel, M. E., Bartz, S. R., Schweickart, V. L., Raport, C. J., & Emerman, M. (1997) · Virology · doi:10.1006/viro.1997.8606 · Cited by 207
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes
Martin, L., Stricher, F., Missé, D., Sironi, F., Pugnière, M., Barthe, P., Prado-Gotor, R., Freulon, I., Magne, X., Roumestand, C., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt768 · Cited by 188
Aptamers against extracellular targets for in vivo applications
Pestourie, C., Tavitian, B., & Duconge, F. (2005) · Biochimie · doi:10.1016/j.biochi.2005.04.013 · Cited by 183
Fitzwater, T., & Polisky, B. (1996) · Methods in Enzymology · doi:10.1016/s0076-6879(96)67019-0 · Cited by 172
Escort aptamers: a delivery service for diagnosis and therapy
Hicke, B. J., & Stephens, A. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11324 · Cited by 169
Khati, M., Schüman, M., Ibrahim, J., Sattentau, Q., Gordon, S., & James, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12692-12698.2003 · Cited by 169
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA
Amarzguioui, M., Lundberg, P. S., Cantin, E. M., Hagstrom, J. E., Behlke, M. A., & Rossi, J. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.72 · Cited by 145
Self-citationKeynote review: Progress in targeting HIV-1 entry
Ryser, H. J. ‐., & Flückiger, R. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03550-6 · Cited by 116
Chemical Modification Patterns Compatible with High Potency Dicer-Substrate Small Interfering RNAs
Collingwood, M. A., Rose, S. D., Huang, L., Hillier, C., Amarzguioui, M., Wiiger, M. T., Soifer, H. S., Rossi, J. J., & Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0123 · Cited by 112
Self-citationWeiss, C. D., & White, J. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.12.7060-7066.1993 · Cited by 108
The role of CD4 in HIV binding and entry
Sattentau, Q. J., & Moore, J. P. (1993) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1993.0136 · Cited by 90
Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 Study
Shearer, W. T., Israel, R. J., Starr, S. E., Fletcher, C. V., Wara, D. W., Rathore, M. H., Church, J. A., Deville, J. G., Fenton, T., Graham, B., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/317622 · Cited by 78
HIV-1 entry – an expanding portal for drug discovery
Blair, W. S., Lin, P., Meanwell, N. A., & Wallace, O. B. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01484-7 · Cited by 72
HIV-1 entry inhibitors: new targets, novel therapies
Pierson, T. C., & Doms, R. W. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00235-3 · Cited by 34
Cited by
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Self-citationThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Self-citationAnalysis of aptamer discovery and technology
Dunn, M. R., Jimenez, R. M., & Chaput, J. C. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0076 · Cited by 938
Aptamer in Bioanalytical Applications
Iliuk, A. B., Hu, L., & Tao, W. A. (2011) · Analytical Chemistry · doi:10.1021/ac201057w · Cited by 762
Metadata
- Authors
- Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., & Rossi, J. J.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-21
- Volume
- 37
- Issue
- 9
- Pages
- 3094-3109
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2137109655
- Cited by
- 267
- References
- 44
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.